Hudson Bay Capital Management
MRNS

Hudson Bay Capital Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Hudson Bay Capital Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-72,016
Closed -$287K – 1066
2022
Q4 		$287K Buy
72,016
+56,763
+372% +$279K ﹤0.01% 739
2022
Q3 		$101K Buy
+15,253
New +$93.9K ﹤0.01% 940

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Hudson Bay Capital Management's MRNS Position: Q1 2023 in Review

Hudson Bay Capital Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2023, closing a stake of 72,016 shares — an estimated $287K sold.

Hudson Bay Capital Management first reported a position in MRNS in Q3 2022 and held it in 2 quarters. The position peaked at $287K in Q4 2022. 86 funds tracked by Wall St. Rank hold MRNS as of Q1 2023.

  • Hudson Bay Capital Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2023 after selling out during the quarter.
  • Hudson Bay Capital Management sold 72,016 Marinus Pharmaceuticals, Inc shares in Q1 2023, an estimated $287K.
  • Hudson Bay Capital Management first reported a position in Marinus Pharmaceuticals, Inc in Q3 2022 and held it in 2 quarters.
  • Hudson Bay Capital Management's Marinus Pharmaceuticals, Inc position peaked at $287K in Q4 2022.
  • 86 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2023.

Based on Hudson Bay Capital Management's 13F filing for Q1 2023, filed 15 May 2023.